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Exogenous gangliosides inhibit interleukin 2 (IL%)-dependent growth of a T cell line, AKIL-l.E8. IL2 
activity is retained by columns of ganglioside covalently linked to poly(L-lysine)-agarose and is not eluted 
with ethylene glycol but is completely recovered by elution with 1”lo SDS. The ability of gangliosides to 
inhibit IL2 activity is directly related to the complexity of their carbohydrate portion, and related ceramide 
derivatives at similar concentrations do not inhibit IL2 activity. We conclude that IL2 bound to exogenous 
gangliosides is inactive and that the carbohydrate portion of the ganglioside is crucial to its interaction 
with IL2. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Gangliosides have been implicated in the mito- 
genie response of lymphocytes [l-4]. Mitogenic 
stimulation of T lymphocytes is a multi-step pro- 
cess involving production and action of IL2 PI. 
Here we report that IL2-dependent T cell growth is 
inhibited by exogenous gangliosides and that in- 
hibition is due to binding of IL2 to the glycolipid 
molecules. Our data suggest that T cell prolifera- 
tion might be initiated by the interaction of IL2 
with membrane gangliosides. 
2. I. Materials 
Abbreviations: IL2, interleukin 2; PBS, phosphate buffer; 
EG, ethylene glycof; Hepes, N-hydroxyethylpiperazine- 
N-2-ethanesulfonic acid; BSA, bovine serum albumin; 
globoside, GalNAc~1-3Gal~l-4Galp1-4Glc-Cer; GMs, 
NeuNAccv2-3Gal@l-4Glc-Cer; GM2, GalNAc,&l-4[Neu- 
NAca2-3]Gal/31-4Glc-Cer; GM1, Galal-3GalNAcPl- 
4[NeuNAc~2-3]-Galfl1-4Glc-Cer; GDla, NeuNAccu2- 
3GalB1-3GalNAc,&1-4[NeuNAc(u2-3]Gal~1-4Glc-Cer; 
GDlb, GalPl-3GalNAcfil-4[NeuNAccr2-8 NeuNAcLu2- 
3]GalPl-4Glc-Cer; GTlb, NeuNAccu2-3GalPl-3[Neu- 
NAc(u2-8 NeuNAccu2-3]GalNAc~l-4Gal~l-4Glc-Cer 
Human IL2 was obtained from pools of phyto- 
hemagglutinin stimulated lymphocytes from human 
blood and further purified (4OO-fold) by am- 
monium sulfate fractionation, DEAE-Sepharose 
column chromatography and gel filtration [6]. 
This preparation was free of lectin and had no in- 
terferon activity. After gel electrophoresis in 12% 
polyacrylamide with 0.1% SDS, we detect a promi- 
nent band of M, 14 000 and a faint band migrating 
at the M, of the BSA standard (66 000). The purified 
material was purchased from Boehringer Mann- 
heim (Indianapolis, IN). Conditioned medium 
from Con A stimulated BALB/c mouse spleen cells 
was the source of mouse IL2 [7]. Rat IL2 (Rat T 
cell Polyclone) was from Collaborative Research 
(Lexington, MA). 
* Present address: Laboratorio Di Igiene e Profilassi, 
USL, lOA, Firenze, Italy 
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Individual purified gangliosides were supplied 
by Seromed (Munich, FRG) and Supelco (Bella- 
fonte, PA). Mixed gangliosides were supplied by 
Supelco, Sigma (St. Louis, MO) or ICN Pharma- 
ceuticals (Cleveland, OH). Bovine brain cerebro- 
sides were from Sigma and all other glycolipids 
were from Supelco. 
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2.2. IL2 assay 
IL2 activity was assayed by the growth response 
of an IL2-dependent cloned T cell line (AKIL-1 .ES) 
[8]. AKIL cells do not grow in the absence of IL2, 
but respond to IL2 preparations of mouse, rat or 
human origin. AKIL cells are cultured in complete 
medium (Dulbecco’s modified Eagle medium with 
added 10mM Hepes, 14pM folic acid, 2mM L- 
glutamine, 0.3 mM arginine-HCl, 0.2 mM aspara- 
gine, 1 mM sodium pyruvate, 50pM 2-mercapto- 
ethanol, 100 units/ml penicillin, lOOpg/ml strepto- 
mycin sulfate) supplemented with 5% fetal bovine 
serum and IL2. 
For measurement of IL2 activity, lo4 AKIL cells 
were cultured in 0.2 ml medium containing the 
dilution of IL2 for assay. For the last 24 h of a 
3-day culture period, cells were supplied with 
0.5&i [ 3H] thymidine. Cells were collected on 
glass fiber filters and washed repeatedly with saline 
on a Bellco Cell Harvester. Dried filter discs were 
subjected to liquid scintillation counting. Thymi- 
dine uptake was a consistent measure of cell pro- 
liferation. By definition 1 unit of IL2 generates 
50% of maximum uptake normalized to a standard 
preparation lOOunits/ml (Rat T cell Polyclone). 
2.3. Ganglioside inhibition 
Gangliosides from bovine brain were used either 
in solution or immobilized on poly(L-lysine)- 
agarose by covalent attachment using the carbodi- 
imide procedure [9]. Agarose beads were counted 
in a Nageotte hemacytometer. 
Columns of agarose-ganglioside beads were pre- 
pared in plastic pipette tips and washed with 10 
column volumes complete medium supplemented 
with 50mg/ml BSA. A control column contained 
poly(L-lysine)-agarose beads to which sodium ace- 
tate had been covalently linked under conditions 
identical to those for coupling of gangliosides. 
Sialic acid was determined by the resorcinol- 
HCl method [lo]. Protein was determined by the 
fluorescamine [l l] and Bradford methods [12] 
using a BSA standard. 
3. RESULTS 
The growth of IL2-dependent T cells (AKIL) is 
inhibited in a dose-dependent manner when the 
culture medium contains a mixture of bovine brain 
gangliosides in addition to either mouse or human 
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Fig. 1. Inhibition of IL2 activity by bovine brain ganglio- 
sides. Left: human IL2 (2.2 units) (0) and mouse IL2 
(1.4 units) (A) were preincubated with varying concen- 
trations of bovine brain gangliosides prior to the addi- 
tion of AKIL cells. Each point indicates the mean of 
triplicates. The ganglioside preparation used contained 
0.74pmol of sialic acid per mg. Right: the same bovine 
brain ganglioside mixture was covalently attached to 
poly(L-lysine)-agarose. There were 3 x 10-3pmol of 
sialic acid per 104 beads. Rat IL2 (1.2 units) was preincu- 
bated with ganglioside-beads and then AKIL cells were 
added and the standard assay performed. (0) Ganglio- 
side beads, (0) underivatized beads. 
IL2 (fig.1). The gangliosides are not toxic since 
preincubation of cells for 6 h with the same gang- 
lioside mixture, followed by washing and subse- 
quent culture in the presence of IL2, does not 
decrease thymidine uptake. Furthermore, ganglio- 
sides added after 42 or 66 h do not decrease thymi- 
dine uptake induced by IL2. The inhibitory effect 
of gangliosides persisted after the same ganglioside 
mixture was covalently attached to polylysine- 
agarose beads and then added to the cells (fig.1). 
In contrast, control polylysine-agarose beads are 
only slightly inhibitory. Since the agarose beads 
are many times bigger than the cells, it is not likely 
that the inhibitory action of gangliosides is due to 
their uptake into the cells. Inhibition of growth by 
agarose-ganglioside beads is not caused by release 
of free gangliosides into the solution as judged 
from the absence of IL2 inhibitory material in 
supernatants of these beads after incubation at 
37°C for 4 days. 
Since the major gangliosides in the ganglioside 
mixture used are monosialoganglioside GMl, the 
disialogangliosides GDla and GDl b, and the 
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trisialoganglioside GTl b [ 131, we investigated their 
effects individually. All 4 gangliosides inhibit 
human IL2 activity (fig.2), yielding 50% inhibition 
of thymidine uptake at concentrations from 5 to 
25 pM. All 4 gangliosides inhibit IL2 activity of rat 
or mouse origin in the same range (not shown). 
If a series of individual purified gangliosides is 
compared in the ability to inhibit human IL2 
activity, the molar concentration that produces 
50% reduction in thymidine uptake decreases as 
the complexity of the carbohydrate portion of the 
molecule increases (e.g., GM3, 60pM; GM2, 
20pM; GMl, 13pM; GDla, 8,uM). Similar con- 
centrations of related ceramide derivatives with 
less carbohydrate complexity (bovine brain cere- 
brosides, Gaucher’s cerebroside, lactosyl cera- 
mide, ceramide trihexoside and globoside) do not 
inhibit either human or rat IL2. 
To demonstrate that the inhibition of growth is 
due to direct interaction between IL2 and ganglio- 
sides, IL2 solutions were passed through columns 
containing agarose-ganglioside beads. These col- 
umns bound growth promoting activity contained 
in IL2 preparations of rat and human origin (table 
1). The activity of IL2 added to eluates of ganglio- 
side columns that have been washed only with 
complete medium plus BSA is the same as IL2 
Fig.2. Inhibition of IL2 activity by individual ganglio- 
sides. Individual gangliosides of varying concentrations 
were preincubated with 2.2 units human IL2 prior to the 
addition of AKIL cells. Each point represents the mean 
activity measured in the presence of complete 
medium plus BSA that has not passed through the 
column. Therefore, the failure to observe growth 
stimulation by column eluates is not due to the 
presence of gangliosides that have been released 
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of triplicates. 
Table 1 
Binding of IL2 to ganglioside beads 
Column derivative 
Ganglioside 
Ganglioside 
Ganglioside 
Ganglioside 
Ganglioside 
Acetate 
Column IL2 
volume (ml) source 
0.5 rat 
0.4 rat 
0.5 rat 
0.5 human 
0.2 human 
0.5 human 
Units Units not retained Units eluted Second 
applied (Ore of applied) ((70 of applied) eluant (To) 
26 ND 
80 ND 95 1% SDS’ 
120 8 
11 ND 
5 ND 5 20% EGb 
11 73 
a Column 2 was further eluted with 4 column volumes of complete medium supplemented with 1% SDS. The eluate 
was diluted and assayed for IL2 
b Column 5 was prepared with PBS (pH 7.4) supplemented with 50/cg/ml BSA. After IL2 was applied and the column 
washed with PBS, the column was eluted with 4 column volumes of 50% ethylene glycol in PBS. The eluate was 
dialyzed against PBS and then assayed for IL2. Control IL2 that had been diluted 1: 1 with 50% EG in PBS and then 
dialyzed with the column eluates retained full activity. ND, not detectable 
Columns were prepared as described in section 2. IL2 was applied to the column and the material that passed through 
the column was collected along with a wash of 2 column volumes of complete medium plus 50pg/ml BSA. The pooled 
eluate was assayed for IL2 to determine the units not retained by the column 
393 
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from the agarose beads and block IL2 activity that 
itself has not been retained by the column. In con- 
trast, more than 70% of the IL2 activity applied is 
not retained by a column of acetate-agarose beads. 
The interaction between IL2 and ganglioside- 
agarose beads is not reversed by treatment with 
ethylene glycol; but all the activity is eluted from 
the column under conditions where the protein was 
denatured with 1% SDS (table 1). 
The ability of the ganglioside-bead columns to 
retain IL2 activity suggests that IL2 binds to gang- 
liosides. The possibility that the IL2 binds to pro- 
tein in the ganglioside preparations is unlikely. The 
ganglioside preparations contain small amounts of 
protein (l-4%). However, treatment of ganglio- 
sides with proteases (0.3 mg/ml trypsin or 
0.25 mg/ml pronase) for 24 h prior to use fails to 
reduce their inhibition of human or rat IL2 
activity. Ganglioside free cultures to which IL2 
was added after inactivation of the proteases 
demonstrated normal growth. In addition, heating 
gangliosides (lOO°C for 15 min) does not reduce 
their inhibitory effect. 
4. DISCUSSION 
These results explain the ability of gangliosides 
to inhibit the mitogenic response of lymphocytes to 
IL2. Gangliosides bind IL2 and IL2 associated 
with gangliosides in solution cannot support T cell 
growth. The data agree with other reports that 
blastogenesis inhibited when exogenous ganglio- 
sides are added to mitogen or lymphokine stimu- 
lated lymphocyte cultures [l-4]. 
One interpretation of this phenomenon is that 
the IL2 ganglioside binding which occurs in solu- 
tion is representative of a similar interaction which 
normally occurs at the cell membrane. Others have 
shown that when chemically substituted ganglio- 
sides are incorporated into thymocyte cell mem- 
branes, cross-linking of the modified gangliosides 
with multivalent ligands specific for the ganglio- 
side substituents leads to increased DNA synthesis 
[14,15]. The cross-linking of cell membrane gang- 
liosides by multivalent ligands could stimulate 
DNA synthesis either directly, by mimicking the 
growth effect of IL2, or indirectly by initiating IL2 
synthesis. The observations presented here suggest 
that membrane gangliosides or closely related 
structures interact with IL2 resulting in lympho- 
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cyte stimulation and further suggest hat produc- 
tive interaction of IL2 with target cells involves 
membrane-bound gangliosides or closely related 
structures. 
Recently anti-Tat, a monoclonal antibody 
directed against a T lymphocyte surface antigen, 
has been shown to block IL2 activity and prevent 
binding of radiolabelled IL2 to a human cell line 
[16]. The highly glycosylated protein that binds 
anti-Tat has been proposed as a receptor for IL2 
[17,18]. However, the data do not rule out the pos- 
sibility that anti-Tat can also bind glycolipids or 
that glycolipids are intimately associated with the 
protein immunoprecipitated by anti-Tat. Anti- 
bodies that recognize both protein and glycolipid 
molecules have been described elsewhere [19] and 
the co-purification of protein and lipid is well 
known [20,21]. Our data suggest that protein is not 
responsible for the interaction of IL2 with ganglio- 
sides since rigorous heat or protease treatment of 
ganglioside preparations does not reduce IL2 inhi- 
bition. However, it remains possible that in the cell 
both glycoprotein and glycolipid act co-operatively 
in binding IL2 or that they bind IL2 with different 
affinities. 
The specificity of the ILZganglioside interaction 
is indicated by the fact that other glycolipids struc- 
turally related to gangliosides do not inhibit IL2 
activity. Furthermore, the ability of gangliosides to 
inhibit IL2 activity is directly related to the com- 
plexity of their carbohydrate moiety. This indi- 
cates that the carbohydrate portion of gangliosides 
is crucial to their interaction with IL2 and that the 
IL2-ganglioside interaction is more than a simple 
hydrophobic interaction. This conclusion is fur- 
ther supported by the failure of ethylene glycol to 
reverse the IL2-ganglioside interaction. Also, N- 
acetylglucosamine, a monosaccharide present in 
some gangliosides, has been shown to inhibit IL2 
activity on rat thymocytes [22]. Thus, the binding 
of IL2 to gangliosides is primarily carbohydrate 
specific although some hydrophobic association 
may also occur. 
ACKNOWLEDGEMENTS 
This work was supported by grants from the 
American Cancer Society (BC-384), the United 
States National Institutes of Health (AI-15007) 
and the United States National Science Foundation 
Volume 170, number 2 FEBS LETTERS May 1984 
(PCM 8024539). We thank Chiu-Yang Shih for 
kindly supplying us with AKIL 1.E8 cells. We 
thank Lynn Sabinash for technical assistance. 
REFERENCES 
[l] Miller, H.C. and Esselman, W.J. (1974) J. 
Immunol. 115, 839-843. 
[2] Lengle, E.E., Krishnaraj, R. and Kemp, R.G. 
(1979) Cancer Res. 39, 817-822. 
[3] Yates, A.J., Hitchcock, C.L., Stewart, S.S. and 
Whisler, R.L. (1980) ACS Symposium Series 128, 
419-433. 
I41 
PI 
El 
171 
WI 
[91 
[101 
Merritt, W.D., Tate, N.S., Bailey, G.M., Goldstein, 
A.L. and Pluznik, D.H. (1982) Immunobiology 
163, 392. 
Larsson, E.L., Iscove, N.N. and Coutinho, A. 
(1980) Nature 283, 664-666. 
Mier, J.W. and Gallo, R.C. (1980) Proc. Natl. 
Acad. Sci. USA 77, 6134-6138. 
Smith, K.A., Baker, P.E., Gillis, S. and Ruscetti, 
F.W. (1980) Mol. Immun. 17, 579-589. 
Shih, C., Truitt, R.L., Andreani, M. and Bortin, 
M.M. (1983) In Vitro 19, 759-766. 
Cuatrecasas, P., Parikh, I. and Hollenberg, M.D. 
(1973) Biochemistry 12, 4253-4264. 
Svennerholm, L. (1957) Biochim. Biophys. Acta 
24, 604-611. 
[ll] Udenfriend, S., Stein, S., Bohlen, P., Dairman, 
W., Leimgruber, W. and Weigele, M. (1972) 
Science 178, 871-872. 
[12] Bradford, M. (1976) Anal. Biochem. 72, 248-254. 
[13] Ledeen, R.W. and Yu, R.K. (1976) in: Glycolipid 
Methodology (Witting, L.A. ed) pp. 187-214, 
American Oil Chemists’ Society, Champaign, IL. 
[14] Spiegel, S., Ravid, A. and Wilchek, M. (1979) 
Proc. Natl. Acad. Sci. USA 76, 5277-5281. 
[15] Spiegel, S. and Wilchek, M. (1981) J. Immunol. 
127, 572-575. 
[16] Leonard, W.J., Depper, J.M., Uchiyama, T., 
Smith, K., Waldmann, T.A. and Greene, W.C. 
(1982) Nature 300, 267-269. 
[17] Robb, R. J. and Greene, W. (1983) J. Exp. Med. 
158, 1332-1337. 
[18] Leonard, W.J., Depper, J.M., Robb, R.J., 
Waldmann, T.A. and Greene, W. (1983) Proc. 
Natl. Acad. Sci. USA 80, 6957-6961. 
1191 Fredman, P., Richert, N.D., Magnani, J.L., 
Willingham, M.C., Pasten, I. and Ginsburg, V. 
(1983) J. Biol. Chem. 285, 11206-11210. 
[20] Dejter-Juszynski, M., Harpaz, N., Flowers, H.M. 
and Sharon, N. (1978) Eur. J. Biochem. 83, 
363-373. 
[21] Watanabe, K., Hakomori, S., Powell, M.E. and 
Yohota, M. (1980) Biochem. Biophys. Res. Com- 
mun. 92, 638-646. 
[22] Ulrich, F. (1983) Cell. Immun. 80, 241-256. 
395 
